Streetwise Articles



Cancer Targeting Drug Better Tolerated Than Others
  (5/27/22)
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report. More >


50% Revenue Growth Expected This Year for Biopharma Co.
  (5/26/22)
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report. More >


Trial Shows Colon Cleansing Device to Be Effective
  (5/26/22)
"The positive results could drive physician adoption when scheduling colonoscopies for hard-to-prepare patients going forward," noted an H.C. Wainwright & Co. report. More >


FDA Approves New Skin Resurfacing Device
Source: Streetwise Reports  (5/26/22)
Apyx Medical Corp. shares traded 50% higher after the company reported it received U.S. FDA 510(k) clearance for its Renuvion Dermal Handpiece for use in specific cosmetic dermal resurfacing procedures. More >


Target Price on Drug Co. Suggests Possible Huge Returns
  (5/25/22)
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report. More >


Cannabis Firm Posts Improved Q2 FY22 YOY
  (5/23/22)
Compared to the previous year, the company's overall operating results for the quarter are better, noted a Noble Capital Markets report. More >


Innoviva Buys Remaining Shares in Advanced Antibiotic Co.
Source: Streetwise Reports  (5/23/22)
Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share. More >


H2/22 Slated to Be Catalyst Rich for Pharma Co.
  (5/21/22)
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs. More >


US Pharma Co. Granted FDA Approval for IV Smallpox Drug
Source: Streetwise Reports  (5/20/22)
SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox. More >


New Improved Drug Expected to Get FDA Approval Next Month
  (5/20/22)
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock. More >


Firm Reports Encouraging Trial Results in Cystinosis
  (5/19/22)
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc. More >


EU Co. Secures Smallpox Vaccine Order to Target Monkeypox
Source: Streetwise Reports  (5/19/22)
Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox. More >


Coverage Launched on Co. in Alzheimer's Drug Space
  (5/17/22)
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report. More >


Clinical Catalysts for Biotech's Stock On Track for Mid 2022
  (5/15/22)
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report. More >


Biopharma Co. to Launch Two Clinical Trials This Year
  (5/14/22)
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report. More >


Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm
Source: Streetwise Reports  (5/13/22)
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development, and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer. More >


First Results From Biotech Co.'s Lymphoma Program Are Impressive
  (5/13/22)
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report. More >


Pfizer Offers $11.6B to Buy Biopharma Co.
Source: Streetwise Reports  (5/10/22)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities. More >


Ophthalmic Med Tech. Firm Sees 166% Gain in LAL Implants
Source: Streetwise Reports  (5/6/22)
Shares of RxSight Inc. traded 7% higher after the company reported Q1/22 financial results which highlighted a 157% YoY increase in revenue and a 208% increase in unit sales of its Light Delivery Devices (LDD™s) utilized in cataract surgery procedures to implant its RxSight Light Adjustable Lens® (LAL), which it says is "the world's first and only adjustable intraocular lens (IOL) that is customized after cataract surgery." More >


Analyst Says Avivagen Is a Strong Buy
Source: Clive Maund  (5/5/22)
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy. More >


Biopharma Co. Licenses Orphan Drug to UK Firm for $450M
Source: Streetwise Reports  (5/5/22)
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver. More >


Pilot Launch of VLN Cigarettes in Progress
  (5/3/22)
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report. More >


FDA Expands Use for Transcarotid Stent
Source: Streetwise Reports  (5/2/22)
Silk Road Medical Inc. shares traded 12% higher after the company reported that the U.S. FDA granted expanded authorization for its ENROUTE® transcarotid stent system for use in preventing stroke in patients deemed to be at standard risk for adverse events from carotid endarterectomy. More >


Biotech Co. Advances COVID-19 Vaccines Toward Approval
  (5/1/22)
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report. More >


Is Reliq Health Technologies a Nutrimental 'Buy'?
Source: Clive Maund  (4/29/22)
After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'. More >


Showing Results: 26 to 50 of 2127 Prev Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts